West Pharmaceutical Services (WST) Cash from Investing Activities (2009 - 2026)

West Pharmaceutical Services has disclosed Cash from Investing Activities across 18 years of filings, most recently posting -$42.7 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$42.7 million, up 40.11% year-over-year; the trailing twelve-month figure through Mar 2026 was -$257.3 million (up 28.41% YoY), and the FY2025 annual result was -$285.9 million, up 24.5% from the prior year.
• Cash from Investing Activities came in at -$42.7 million for Q1 2026 at West Pharmaceutical Services, up from -$76.1 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of -$42.7 million in Q1 2026 to a low of -$108.8 million in Q4 2023.
• The 5-year median for Cash from Investing Activities is -$82.1 million (2023), against an average of -$80.2 million.
• Across the five-year window, Cash from Investing Activities sank 61.93% in 2023 and jumped 40.11% in 2026, its largest moves.
• West Pharmaceutical Services' Cash from Investing Activities stood at -$94.8 million in 2022, then slipped by 14.77% to -$108.8 million in 2023, then climbed by 3.68% to -$104.8 million in 2024, then increased by 27.39% to -$76.1 million in 2025, then soared by 43.89% to -$42.7 million in 2026.
• The last three Cash from Investing Activities figures came in at -$42.7 million (Q1 2026), -$76.1 million (Q4 2025), and -$63.3 million (Q3 2025), per Business Quant data.